Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Point of Care PrEP Delivery for Young Black MSM and Transgender Women
NCT04329442Withdrawn
- Sponsor
- University of Chicago
- Start
- Apr 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by University of Chicago. Primary endpoints: Intention to Continue PrEP at 4 months and PrEP Adherence at 4 months. Planned start Apr 2020; status: withdrawn.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04329442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329442.